
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TXTM | +330% | -15.69% | -3.35% | +1,250% |
| S&P | +13.95% | +78.35% | +12.25% | +207% |
ProText Mobility, Inc. engages in the development of pharmaceutical applications for botanical drugs. It has license to develop Phytofare, which is a bioavailable extract produced from live green tea leaves that has been clinically proven in double-blind human trials to have ten-times greater bioavailability over generic extract. The company was founded on September 5, 2001 and is headquartered in Miami, FL.
No news articles found for ProText Mobility.
| Q1 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 0.0% |
| Market Cap | $1.75M | -47.1% |
| Net Income | -$4.73K | 76.4% |
| EBITDA | -$3.63K | 81.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q1 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.00K | 0.0% |
| Inventory | 255 | 1600.0% |
| Q1 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $112.23K | 61.1% |
| Q1 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -0.02% | 0.4% |
| Return On Invested Capital | 11.57% | -24.5% |
| Q1 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4.10K | 43.6% |
| Operating Free Cash Flow | -$4.10K | 43.6% |
| Metric | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.61 | 1.17 | 0.16 | 0.15 | -86.04% |
| Price to Tangible Book Value | 0.61 | 1.16 | 0.16 | 0.15 | -86.00% |
| Enterprise Value to EBITDA | -1958.12 | -1359.76 | -3048.69 | -2211.34 | 185.81% |
| Return on Equity | -0.1% | -0.1% | -0.0% | -0.0% | -95.05% |
| Total Debt | $76.25K | $86.93K | $108.13K | $112.23K | 61.06% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.